Axsome Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Axsome Therapeutics announced robust revenue increases for its key products AUVELITY, SUNOSI, and SYMBRAVO, but also reported substantial operating losses.
NASDAQ
Axsome Therapeutics announced its first-quarter 2026 financial results, highlighting significant revenue growth driven by its key products.
NASDAQ
Axsome Therapeutics reported significant revenue increases and a reduced net loss for the nine months ended September 30, 2025, driven by strong product sales and new product launches.
NASDAQ
Axsome Therapeutics reported significant revenue growth driven by its commercial products and secured a new $570 million debt facility, while continuing to advance its pipeline and manage ongoing legal and regulatory challenges.
NASDAQ
Axsome Therapeutics announces strong Q1 2025 financial results, with total revenue increasing to $121.5 million driven by product sales and royalty revenue.
NASDAQ
10-Q: Axsome Therapeutics Reports Q3 2024 Results: Revenue Growth Driven by Auvelity and Sunosi Sales
Axsome Therapeutics' Q3 2024 results show significant revenue growth driven by increased sales of Auvelity and Sunosi, alongside ongoing clinical development programs.
NASDAQ
10-Q: Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Axsome Therapeutics reports a net loss of $79.3 million for the second quarter of 2024, with product sales reaching $86.5 million.
NASDAQ
Axsome Therapeutics' first quarter 2024 results show significant revenue growth driven by increased sales of Auvelity and Sunosi, alongside ongoing clinical development programs.